A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia

Summary

To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious adverse events attributable to 566C80.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications